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Abstract 
 
Introduction: Resectional surgery remains the mainstay of treatment for colorectal cancer. A 
heightened postoperative systemic inflammatory response has been shown to correlate 
negatively with short/long-term outcomes. Perioperative steroid administration may help to 
alleviate this systemic inflammatory response. This survey has been carried out to assess 
current attitudes towards perioperative steroid use and to gauge interest in a randomised 
control trial in this area.  
 
Method: An internet-based survey consisting of 9 questions was circulated via email. Those 
responses from outside the United Kingdom were excluded.   
 
Result: 74 doctors from the United Kingdom, predominantly Consultant Anaesthetists (54%) 
responded to this survey. 77% gave some or all of their patients steroids, in 75% of cases at 
the discretion of the anaesthetist. The main perceived benefit was to reduce postoperative 
nausea and vomiting. Diabetics and those deemed at high risk of wound infection were the 
group in whom most respondents would be reluctant to give steroids.  32% of respondents 
had no concerns. 87% of respondents felt that that a randomised trial in this field would be of 
clinical interest with most respondents (58%) preferring a three-armed trial – no steroids vs 
low dose steroids vs high dose steroids.  
 
Conclusion – This survey indicated that perioperative steroid use is currently widespread. 
Sufficient equipoise exists for a trial in this area with regard to examining the impact of 
dexamethasone on postoperative complications and the postoperative systemic inflammatory 
response. Respondents favoured a 3-armed trial – no steroids vs low-dose steroids vs high-
dose steroids.  
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Introduction 
 
Colorectal cancer is the third most commonly diagnosed malignancy worldwide with 
approximately 1.8 million new cases being diagnosed each year(1). Within the United 
Kingdom colorectal cancer accounts for around 16,000 deaths annually(2). Curative 
resectional surgery remains the mainstay of treatment for this condition though carries with it 
not only a significant risk of overall morbidity and mortality but also a significant risk of 
cancer related mortality even after curative treatment. 
 
The relationship between an increased postoperative systemic inflammatory response and 
increased likelihood of complications has now been well documented within the medical 
literature(3-5) as has the relationship between the postoperative systemic inflammatory 
response, postoperative complications and long-term oncological outcome and survival(5-7). 
The potential to modulate the postoperative systemic inflammatory response is therefore of 
clinical interest as one would hypothesise that this may reduce postoperative morbidity and 
mortality and improve long-term cancer free survival.  
 
Single dose corticosteroids are frequently administered in the perioperative period to reduce 
postoperative nausea and vomiting(8-10). A previous retrospective propensity matched 
observational study from our department that included patients undergoing elective 
resectional surgery for colorectal cancer demonstrated a reduction in both the magnitude of 
the postoperative systemic inflammatory response and the overall complication rate in those 
patients who received single dose dexamethasone on induction of anaesthesia(11). While a 
recent large randomised control trial(10) documented the beneficial effect of single dose 
dexamethasone on postoperative nausea and vomiting it did not measure the postoperative 
systemic inflammatory response. The administration of preoperative corticosteroids appears 
to be safe with a previous meta-analysis(12) not demonstrating any association between 
preoperative corticosteroid administration and an increased risk of any complications 
including anastomotic leaks (p=0.79). 
 
This qualitative questionnaire-based study aimed to examine both attitudes towards and 
current practice of perioperative steroid administration in resectional colorectal surgery. This 
would improve knowledge of current perioperative steroid use and perceived benefits and 
risks of this adjunct to anaesthesia. It would also help to assess whether there is current 
equipoise to carry out further research in this area including the effect of perioperative steroid 
use on the postoperative systemic inflammatory response, morbidity and mortality within the 
context of curative colorectal cancer surgery. 
 
 
 
 
  
3 
 
Methods 
 
This qualitative analysis utilised an internet based survey which was generated on the 
SurveyMonkey website(13) and included 9 questions regarding the use of perioperative 
steroids in resectional colorectal cancer surgery (Table 1).  
Question 1: In which country/region do you work in? 
a. United Kingdom d. Australia 
b. Europe e. Other (please specify) 
c. USA  
Question 2: What is your grade and speciality? 
a. Anaesthetist (Consultant) e. Consultant Surgeon (Non-Colorectal) 
b. Anaesthetist (Trainee) f. Career Grade Surgeon 
c. Anaesthetist (Other) g. Surgical Trainee 
d. Consultant Surgeon (Colorectal) h. Other (please specify) 
Question 3: Do any of your patients receive steroids in the perioperative period? If yes, please specify the drug and 
dose or unknown if unsure. 
a. Yes (all) c. No 
b. Yes (some) a. Unsure 
Question 4: If you answered yes to Question 3 who makes the decision regarding administration of steroids? If you 
answered no to Question 3 please select N/A 
a. Surgeon d. Part of ERAS or similar protocol  
b. Anaesthetist e. N/A 
c. Combination  
Question 5: If you answered yes to Question 3 when are steroids given to patients? If you answered no to Question 
3 please select N/A 
a. Preoperatively c. Post-operatively 
b. Intra-operatively/on induction of 
anaesthesia 
d. N/A 
Question 6: Are there any groups of patients to whom you would be reluctant to give perioperative steroids? 
(Select all that apply) 
a. Diabetics (diet/tablet controlled) d.  High risk of wound infection 
b. Diabetics (insulin controlled) e. Emergency cases 
c. Renal failure f. Other (please specify) 
Question 7: Do you think that single dose steroids given perioperatively for colorectal cancer are associated with? 
(Select all that apply) 
a. Reduced postoperative nausea/vomiting e. Reduced postoperative mortality 
b. Reduced overall complications f. Improved long term survival 
c. Reduced anastomotic leaks g. None of the above 
d. Reduced surgical stress response h. Other (please specify) 
Question 8: Do you have concerns regarding the use of perioperative single dose steroids for patients undergoing 
colorectal cancer resection? (Select all that apply) 
a. Diabetes/hyperglycaemia f. Adrenal complications 
b. Increased wound complications g. Gastric complications 
c. Increased anastomotic leak rate d. Renal failure 
e. Psychiatric/mood problems f. No concerns 
g. Insomnia h. Other (please specify) 
Question 9: If a trial was set up examining steroid administration at induction of anaesthesia for colorectal 
resection, with the aim of addressing the effect on the postoperative systemic inflammatory response and 
complications, do you think there would be sufficient equipoise to recruit for the following: (Please select all that 
you feel would be of interest) 
a. 2-armed trial – steroids vs no steroids c. 3-armed trial – no steroids vs low dose steroids vs high 
dose steroids 
b. 2-armed trial – low vs high dose 
steroids 
d. Insufficient equipoise for a trial in this area 
 
Table 1 – Questions included in online survey 
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Once this survey was generated, the link to it was publicised on our department’s Twitter 
feed. Additionally, a list of email addresses was obtained for surgeons and anaesthetists who 
have published in this area and the access link was circulated to them. As only a minority of 
participants were from outside the United Kingdom we decided to exclude these to provide 
insight into current use of and attitudes towards perioperative steroid administration in the 
United Kingdom.  
 
The survey was circulated in February 2019 and closed for responses in March 2019. No 
incentives were used to encourage participation. Data was analysed and graphs were created 
using Microsoft Office and IBM SPSS Statistics Version 24. This study has been registered 
with the Research Registry – unique identifier “researchregistry5124”. There are no conflicts 
of interest or sources of funding to declare. All responses to this survey were anonymous.  
 
Numerical data has been displayed as numbers and/or percentages to the nearest whole 
number. The variation in responses between surgeons and anaesthetists have been compared 
using the Chi squared test with a two tailed p value of <0.05 being considered statistically 
significant.  
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Results 
 
Overall, 100 people responded to this survey. 97 people answered Question 1, 76% (n=74) of 
whom worked in the UK - only these responses were included in further analysis.  
 
74 people answered Question 2. 54% of respondents were Consultant Anaesthetists, 22% 
Consultant Colorectal Surgeons, 11% Anaesthetic Trainees, 9% Surgical Trainees and 4% 
Consultant Non-Colorectal Surgeons. 
 
70 people answered Question 3. 54% of respondents give some patients steroids in the 
perioperative period, 23% give all patients steroids in the perioperative period, 14% do not 
give any patients steroids in the perioperative period and 9% of respondents were unsure 
whether their patients receive steroids or not. 48 people provided a free text comment 
regarding choice of steroids with greater than 90% using dexamethasone. The majority of 
these who specified a dose administer between 3.3mg and 8mg of dexamethasone 
perioperatively. 
 
70 people answered Question 4. Of those whose patients receive steroids, the decision 
regarding perioperative steroid use was made by anaesthetists in 75% of cases, is protocol 
driven in 12% of cases, made by a combination of surgeons and anaesthetists in 11% of cases 
and made by surgeons in 2% of cases. The remainder do not use perioperative steroids. 
 
70 people answered Question 5. Of those who give perioperative steroids, 90% of 
respondents administer steroids intraoperatively/on induction of anaesthesia, 5% give steroids 
preoperatively and 5% give steroids postoperatively.  
 
67 people answered Question 6 (Figure 1). 63% of respondents would be reluctant to give 
steroids to insulin-controlled diabetics, 45% to those deemed at high risk of wound infection, 
43% to other diabetics, 16% to emergency cases and 6% to patients with renal failure. 10% 
would be reluctant to give steroids to other patients including those who were septic or at 
high risk of delirium. 
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Figure 1 - Are there any groups of patients to whom you would be reluctant to give perioperative steroids?  
 
 
67 people answered Question 7 (Figure 2).  94% of respondents think that perioperative 
steroids reduce postoperative nausea and vomiting, 27% think they reduce the surgical stress 
response, 10% think they reduce overall complications, 6% think they have no beneficial 
effect, 4% think they improve long term survival, 3% think they reduce anastomotic leak rate 
and 3% think they reduce postoperative mortality. 9% of respondents think that they had 
other beneficial effects which, based on free text responses, were predominantly analgesic 
effects. 
 
Figure 2 - Do you think that single dose steroids given perioperatively for colorectal cancer are associated with:  
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66 people answered Question 8 (Figure 3). 55% of respondents would be concerned about 
uncontrolled diabetes/hyperglycaemia, 29% about increased wound complications, 15% 
about increased psychiatric/mood disturbance, 11% about insomnia, 8% about increased 
anastomotic leak rate, 5% about increased adrenal complications and 5% about increased 
gastric complications. 6% of responders had other concerns – based on free text comments 
this was predominantly concern over long term oncological outcomes. 
 
 
Figure 3 - Do you have any concerns regarding the use of perioperative single dose steroids for patients 
undergoing colorectal cancer resection?  
 
 
60 people answered Question 9 (Figure 4). 87% of responders think there would be sufficient 
equipoise for a trial in this area. 58% think there would be sufficient equipoise for a 3-armed 
trial (no steroids vs low dose steroids vs high dose steroids), 32% for comparison of steroids 
vs no steroids and 13% for low vs high dose steroids. 13% of responders do not think there 
would be sufficient equipoise for a trial in this area.  
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Figure 4. If a trial was set up examining steroids administered at induction of anaesthesia, do you think there 
would be sufficient equipoise to assess the following?  
 
As shown in Table 2 when the responses of surgeons (any grade) were compared to  
anaesthetists (any grade) significantly more anaesthetists were concerned about giving 
steroids to non-insulin diabetics (58% vs 14%, p=0.001) and insulin dependent diabetics (80% 
vs 27%, p<0.001). Significantly more anaesthetists were concerned about uncontrolled 
diabetes/hyperglycaemia following steroid administration (73% vs 14%, p<0.001) and a 
higher proportion of surgeons were concerned about the effect of steroids on anastomotic 
leak rate (18% vs 2%, p=0.021). Significantly more surgeons than anaesthetists had either no 
concerns or other concerns regarding steroid administration (55% vs 18% p=0.002).  
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 Surgeon Anaesthetist P 
Groups of patients reluctant to give steroids    
Non-insulin dependent diabetes 3 (14%) 26 (58%) 0.001 
Insulin dependent diabetes 6 (27%) 36 (80%) <0.001 
Renal failure 2 (9%) 2 (4%) 0.451 
High risk wound infection 7 (32%) 21 (47%) 0.247 
Emergency cases 1 (5%) 0 (0%) 0.150 
Other 2 (9%) 3 (7%) 0.723 
    
Associations of steroids    
Reduced postop nausea/vomiting 19 (86) 44 (98%) 0.064 
Reduced overall complications 3 (14%) 4 (9%) 0.551 
Reduced anastomotic leaks 1 (5%) 1 (2%) 0.600 
Reduced surgical stress response 8 (36%) 10 (22%) 0.220 
Reduced postop mortality 1 (5%) 1 (2%) 0.600 
Improved long term survival 2 (9%) 1 (2%) 0.202 
None of the above 1 (5%) 0 (0%) 0.150 
Other 0 (0%) 3 (7%) 0.215 
    
Concerns regarding steroids    
Diabetes/hyperglycaemia 3 (14%) 32 (73%) <0.001 
Increased wound complications 4 (18%) 15 (34%) 0.178 
Increased anastomotic leak rate  4 (18%) 1 (2%) 0.021 
Psychiatric/mood problems 1 (5%) 9 (21%) 0.089 
Insomnia 3 (14%) 4 (9%) 0.572 
Adrenal complications 1 (5%) 2 (5%) 1 
Gastric complications 2 (9%) 1 (2%) 0.210 
Renal failure 0 0 X 
Other 12 (55%) 8 (18%) 0.002 
No concerns 12 (55%) 8 (18%) 0.002 
    
Equipoise for trial    
Steroids vs no steroids 5 (25%) 14 (34%) 0.469 
Low vs high dose steroids 5 (25%) 2 (4.9%) 0.021 
No steroids vs low dose vs high dose 14 (70%) 22 (53.7%) 0.223 
No equipoise for trial 3 (15%) 4 (9.8%) 0.546 
Table 2 – Responses to views of perioperative steroids in surgeons (any grade) compared to anaesthetists (any grade) 
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Discussion 
 
The present study was predominantly completed by Consultant Anaesthetists working in the 
United Kingdom. The majority of respondents gave some/all of their patients intraoperative 
steroids with the decision of whether to administer steroids being at the discretion of the 
anaesthetist in most cases. Reduction of postoperative nausea and vomiting was the primary 
aim of perioperative steroid administration. Reluctance to administer steroids was particularly 
notable for those patients who are diabetic, particularly insulin dependent and those at high 
risk of wound infection. This study suggests that there is sufficient equipoise to carry out a 
randomised control trial examining the impact of dexamethasone on the postoperative 
systemic inflammatory response and complications following colorectal resection with 
respondents indicating that a three-armed trial comprising no steroids vs low dose steroids vs 
high dose steroids would be the preferred format for this.  
 
Based on this survey there is concern regarding the use of perioperative single dose 
dexamethasone within the diabetic cohort of patients, particularly those with insulin 
dependent diabetes. Two recent randomised control trials(14, 15) have reported a significant 
increase in blood glucose levels following dexamethasone administration in both diabetic and 
non-diabetic patients although there was no significant difference in the size of the effect 
between diabetics/non-diabetics in either study. A recent Cochrane review(16). similarly 
reported an increased blood glucose following dexamethasone however evidence was limited 
and there was no evidence of increased negative outcomes as a result of this although diabetic 
patients were excluded from most trials.  
 
A previous meta-analysis(12) analysed the impact of corticosteroids on both postoperative 
complications and the postoperative systemic inflammatory response.  It reported a 
significant reduction in both overall complications and postoperative systemic inflammatory 
response in those patients receiving preoperative corticosteroids although a significant 
reduction in infective complications was seen following surgery for liver but not colorectal 
malignancy. Similarly, a recent propensity matched cohort study(11) which included patients 
undergoing surgery for colorectal cancer reported a significantly lower postoperative 
systemic inflammatory response and overall complications in those patients receiving 
preoperative dexamethasone. A further randomised trial(17) of 73 patients undergoing 
maxillofacial surgery reported a significant reduction in postoperative CRP rise within the 
cohort receiving preoperative dexamethasone.  
 
While a recent large multicentre randomised trial (DREAMS)(10) reported a significant 
reduction in postoperative nausea and vomiting in patients undergoing elective bowel surgery 
who received single dose perioperative dexamethasone it did not investigate the difference in 
postoperative systemic inflammatory response between groups. Although not limited to 
colorectal surgery, the PACMAN trial(18) is currently underway and will include surgical 
complications. However, while CRP levels will be collected, postoperative levels of 
inflammation are not included as either primary or secondary outcomes. The PADDI trial(19) 
is also currently underway and will include surgical site infection as a primary outcome, 
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however this trial neither includes postoperative inflammation as a primary outcome, nor is 
limited to colorectal resections. 
 
Limited literature exists reporting the effect of steroid use on long-term disease-free survival. 
One study comparing 515 patients with stage I-III rectal cancer did report, on multivariate 
analysis, a reduction in disease-free and overall survival in those patients receiving 
intravenous dexamethasone A follow up study(20) of a previously conducted small trial of 43 
patients undergoing colonic resection also reported a higher rate of distant recurrence in those 
patients receiving dexamethasone. However, a recently conducted large propensity matched 
study(21) of 2,729 patients undergoing breast cancer surgery did not find an association 
between perioperative dexamethasone administration and increased recurrence or mortality. 
Furthermore, an observational study(22) of 679 patients undergoing pancreaticoduodenectomy 
for cancer reported improved overall survival in patients given intraoperative dexamethasone.  
 
The present study has a several limitations. This survey is small, particularly for the subgroup 
of analysis comparing responses between surgeons and anaesthetists. To encourage 
participation in the survey we intentionally kept survey length short and questions simple. 
Furthermore, medical professionals who have a greater interest in either perioperative steroid 
use and evidence based medical practice or have stronger opinions either for or against 
perioperative steroid use were more likely to respond and therefore may bias results.  
 
It would be of interest to examine within a randomised control trial the effect of steroid 
administration at induction of anaesthesia on the postoperative systemic inflammatory 
response and postoperative short/long-term outcomes in patients undergoing a curative 
resection for colorectal cancer. An observational study by McSorley et al. 2019(23) suggested 
a dose dependent effect of dexamethasone with higher doses of dexamethasone being 
associated with a reduced postoperative systemic inflammatory response and postoperative 
complications. Therefore, a trial which incorporated a low-dose steroid arm (e.g. 
dexamethasone 4mg) and high-dose steroid arm (e.g. dexamethasone 8mg) would be 
worthwhile.  
 
In summary, this study has suggested that while most patients currently receive perioperative 
steroids with the primary aim of reducing postoperative nausea and vomiting (PONV) they 
are not used routinely for all patients. Furthermore, no consensus exists as to the correct dose, 
even in the context of the prevention of PONV. Sufficient equipoise appears to exist for a 
randomised control trial in colorectal cancer resection, with a three-armed RCT comparing no 
steroids vs low dose steroids vs high dose steroids being the most popular choice of design. 
Ideally, anaesthetic technique would be otherwise standardised. In our opinion such a study 
should include postoperative complications as the primary outcome and a measure of the 
postoperative systemic inflammatory response (e.g. C-reactive protein) as a secondary 
outcome. If included, diabetic patients and those at increased risk of wound infection would 
need close monitoring to ensure that they did not have an unacceptably increased risk of 
complications. Additionally, long term follow up of patients included in such a trial would be 
important, to identify whether perioperative single dose steroid usage alters disease free 
survival, although if not powered for this outcome then it may remain an area of uncertainty.  
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Highlights 
 
• Currently, the use of perioperative steroids is common, although not routine in 
resectional colorectal surgery 
• Perioperative steroids are currently administered primarily at the discretion of the 
anaesthetist with the aim of reducing postoperative nausea and vomiting 
• There is sufficient equipoise to carry out an RCT studying the effect of single dose 
perioperative dexamethasone on postoperative outcomes in colorectal resection 
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